Lesion dose in differentiated thyroid carcinoma metastases after rhTSH or thyroid hormone withdrawal: 124I PET/CT dosimetric comparisons. (Q53282282)

13 May 2018

title

Lesion dose in differentiated thyroid carcinoma metastases after rhTSH or thyroid hormone withdrawal: 124I PET/CT dosimetric comparisons. (English)

1 reference

13 May 2018

differentiated thyroid carcinoma

main subject

1 reference

9

Andreas Bockisch

1 reference

13 May 2018

author name string

Lutz Stefan Freudenberg

1

1 reference

13 May 2018

Walter Jentzen

2

1 reference

13 May 2018

Thorsten Petrich

3

1 reference

13 May 2018

Cornelia Frömke

4

1 reference

13 May 2018

Robert J Marlowe

5

1 reference

13 May 2018

Till Heusner

6

1 reference

13 May 2018

Wolfgang Brandau

7

1 reference

13 May 2018

Wolfram H Knapp

8

1 reference

13 May 2018

publication date

27 July 2010

1 reference

13 May 2018

European Journal of Nuclear Medicine and Molecular Imaging

published in

1 reference

13 May 2018

volume

37

1 reference

13 May 2018

issue

12

1 reference

13 May 2018

page(s)

2267-2276

1 reference

13 May 2018

Compassionate use of recombinant human thyrotropin to facilitate radioiodine therapy: case report and review of literature

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00259-010-1565-3

Area under the curve of TSH after levothyroxine withdrawal versus administration of recombinant human TSH (rhTSH): possible implications for tumor growth

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00259-010-1565-3

Low-activity (2.0 GBq; 54 mCi) radioiodine post-surgical remnant ablation in thyroid cancer: comparison between hormone withdrawal and use of rhTSH in low-risk patients

21 January 2018

1 reference

12 December 2020

Segmentation of PET volumes by iterative image thresholding.

1 reference

12 December 2020

Thyroid remnant dose: 124I-PET/CT dosimetric comparison of rhTSH versus thyroid hormone withholding before radioiodine remnant ablation in differentiated thyroid cancer

1 reference

12 December 2020

124I-PET dosimetry in advanced differentiated thyroid cancer: therapeutic impact.

1 reference

12 December 2020

Value of (124)I-PET/CT in staging of patients with differentiated thyroid cancer.

1 reference

12 December 2020

Thyroid hormone withdrawal in patients with differentiated thyroid carcinoma: a one hundred thirty-patient pilot survey on consequences of hypothyroidism and a pharmacoeconomic comparison to recombinant thyrotropin administration

1 reference

12 December 2020

Iodine excretion during stimulation with rhTSH in differentiated thyroid carcinoma

1 reference

12 December 2020

Thyroid cancer dosimetry using clearance fitting.

1 reference

12 December 2020

Comparison of iodine uptake in tumour and nontumour tissue under thyroid hormone deprivation and with recombinant human thyrotropin in thyroid cancer patients

1 reference

12 December 2020

Modulation of thyroid-specific gene expression in normal and nodular human thyroid tissues from adults: an in vivo effect of thyrotropin.

1 reference

12 December 2020

Evaluation of dosimetry of radioiodine therapy in benign and malignant thyroid disorders by means of iodine-124 and PET

1 reference

12 December 2020

A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal

1 reference

12 December 2020

Comparison of Administration of Recombinant Human Thyrotropin with Withdrawal of Thyroid Hormone for Radioactive Iodine Scanning in Patients with Thyroid Carcinoma

1 reference

12 December 2020

rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review.

1 reference

12 December 2020

Lung dosimetry for radioiodine treatment planning in the case of diffuse lung metastases.

1 reference

12 December 2020

Tumour dosimetry and response in patients with metastatic differentiated thyroid cancer using recombinant human thyrotropin before radioiodine therapy

1 reference

12 December 2020

Recombinant human thyroid-stimulating hormone is effective for radioiodine ablation of post-surgical thyroid remnants

1 reference

12 December 2020

Recombinant human thyrotropin for the diagnosis and treatment of a highly functional metastatic struma ovarii

1 reference

12 December 2020

Optimized 124I PET dosimetry protocol for radioiodine therapy of differentiated thyroid cancer

1 reference

12 December 2020

Preparation with recombinant human thyroid-stimulating hormone for thyroid remnant ablation with 131I is associated with lowered radiotoxicity

1 reference

12 December 2020

Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy.

1 reference

12 December 2020

Recombinant human thyrotropin-assisted radioiodine therapy for patients with metastatic thyroid cancer who could not elevate endogenous thyrotropin or be withdrawn from thyroxine

1 reference

12 December 2020

Defects in iodide metabolism in thyroid cancer and implications for the follow-up and treatment of patients

1 reference

12 December 2020

Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal.

1 reference

12 December 2020

Patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software

1 reference

12 December 2020

Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study.

1 reference

12 December 2020

A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation

1 reference

12 December 2020

Quality of life changes and clinical outcomes in thyroid cancer patients undergoing radioiodine remnant ablation (RRA) with recombinant human TSH (rhTSH): a randomized controlled study.

1 reference

12 December 2020

A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer

1 reference

12 December 2020

The sodium/iodide Symporter (NIS): characterization, regulation, and medical significance

1 reference

12 December 2020

Short-term hypothyroidism after Levothyroxine-withdrawal in patients with differentiated thyroid cancer: clinical and quality of life consequences

1 reference

12 December 2020

Preparation of 124I solutions after thermodistillation of irradiated 124TeO2 targets

1 reference

12 December 2020

Sick leave for follow-up control in thyroid cancer patients: comparison between stimulation with Thyrogen and thyroid hormone withdrawal.

1 reference

12 December 2020

Diagnostic value of high-resolution B-mode and power-mode sonography in the follow-up of thyroid cancer.

1 reference

12 December 2020

10.1007/S00259-010-1565-3

Identifiers

DOI

1 reference

13 May 2018

1 reference

13 May 2018